| Tochi Chibuzor Umunakwe, MD | |
|
10810 Connecticut Ave, Kensington, MD 20895-2138 | |
| (301) 929-7100 | |
| Not Available |
| Full Name | Tochi Chibuzor Umunakwe |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 11 Years |
| Location | 10810 Connecticut Ave, Kensington, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609119577 | NPI | - | NPPES |
| 1609119577 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | T7758 (Texas) | Secondary |
| 207LP2900X | Anesthesiology - Pain Medicine | 62735 (Wisconsin) | Secondary |
| 207L00000X | Anesthesiology | 62735 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center Of El Paso | El paso, TX | Hospital |
| Sanford Bemidji Medical Center | Bemidji, MN | Hospital |
| Entity Name | Texas Tech University Health Sciences Center El Paso |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598705055 PECOS PAC ID: 7517864754 Enrollment ID: O20031216000806 |
News Archive
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.
More than 5 million cancer survivors in the United States experience chronic pain, almost twice the rate in the general population, according to a study published by Mount Sinai researchers in JAMA Oncology in June.
Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide. The researchers found that the microbes block nitric oxide production by subverting the biochemical machinery used by immune cells called macrophages to produce the chemical.
› Verified 1 days ago
| Entity Name | Texas Ams Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174926125 PECOS PAC ID: 9133441769 Enrollment ID: O20141209001912 |
News Archive
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.
More than 5 million cancer survivors in the United States experience chronic pain, almost twice the rate in the general population, according to a study published by Mount Sinai researchers in JAMA Oncology in June.
Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide. The researchers found that the microbes block nitric oxide production by subverting the biochemical machinery used by immune cells called macrophages to produce the chemical.
› Verified 1 days ago
| Entity Name | El Paso Ams Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134740202 PECOS PAC ID: 9931520970 Enrollment ID: O20200601000147 |
News Archive
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.
More than 5 million cancer survivors in the United States experience chronic pain, almost twice the rate in the general population, according to a study published by Mount Sinai researchers in JAMA Oncology in June.
Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide. The researchers found that the microbes block nitric oxide production by subverting the biochemical machinery used by immune cells called macrophages to produce the chemical.
› Verified 1 days ago
| Entity Name | Medway Pain Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912605429 PECOS PAC ID: 1759756844 Enrollment ID: O20230403001051 |
News Archive
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.
More than 5 million cancer survivors in the United States experience chronic pain, almost twice the rate in the general population, according to a study published by Mount Sinai researchers in JAMA Oncology in June.
Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide. The researchers found that the microbes block nitric oxide production by subverting the biochemical machinery used by immune cells called macrophages to produce the chemical.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tochi Chibuzor Umunakwe, MD 10810 Connecticut Ave, Kensington, MD 20895-2138 Ph: (301) 929-7100 | Tochi Chibuzor Umunakwe, MD 10810 Connecticut Ave, Kensington, MD 20895-2138 Ph: (301) 929-7100 |
News Archive
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, has received permission from the Food and Drug Administration to begin a revolutionary Phase 1 clinical trial to evaluate the safety of transplanting human Schwann cells to treat patients with recent spinal cord injuries.
More than 5 million cancer survivors in the United States experience chronic pain, almost twice the rate in the general population, according to a study published by Mount Sinai researchers in JAMA Oncology in June.
Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide. The researchers found that the microbes block nitric oxide production by subverting the biochemical machinery used by immune cells called macrophages to produce the chemical.
› Verified 1 days ago
Ronjeet K Reddy, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10810 Connecticut Ave, Kensington, MD 20895 Phone: 301-929-7100 | |
Dr. Janice Marie Bitetti, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10810 Connecticut Avenue, Kensington, MD 20895 Phone: 301-929-7507 Fax: 301-929-7114 | |
Marya Sonny, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 10810 Connecticut Ave, Kaiser Permanente Kensington Medical Center, Kensington, MD 20895 Phone: 301-929-7100 | |
Dr. Sawsan Said Hanna, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10810 Connecticut Avenue, Kensington, MD 20895 Phone: 301-929-7100 Fax: 301-929-7114 | |
Dr. Elizabeth Victoria Molyneaux, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10810 Connecticut Avenue, Kensington, MD 20895 Phone: 301-929-7100 Fax: 301-929-7114 | |
Yun Wang, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10810 Connecticut Ave, Kensington, MD 20895 Phone: 301-929-7100 | |
Dr. Chanda V Bell-lamarque, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: Kaiser Permanente, 10810 Connecticut Avenue, Kensington, MD 20895 Phone: 301-929-7100 |